ArticleDrug and alcohol dependence2011
Gender differences in pharmacokinetics of maintenance dosed buprenorphine.
Article in Drug and alcohol dependence, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Exploring gender differences in pharmacokinetics of central nervous system related medicines based on a systematic review approach.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.The Journal of pharmacology and experimental therapeutics · 2014Trial
- Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.Drug and alcohol dependence · 2013Trial
- Pharmacokinetics of a Single Subcutaneous Extended-Release Buprenorphine (Ethiqa XR) in Healthy Beagles.Journal of veterinary pharmacology and therapeutics · 2026Article
- Sex differences in hepatic enzymes and transporters involved in pharmacokinetics.Liver research (Beijing, China) · 2025Review
- Proteomic analysis of plasma proteins during fentanyl withdrawal in ovariectomized female rats with and without estradiol.Journal of neuroendocrinology · 2025Article
- Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings.BMC primary care · 2024Article
- Pharmacokinetics of Extended-release Buprenorphine and Clinical Efficacy for Postoperative Pain Management in the Domestic Ferret (Journal of the American Association for Laboratory Animal Science : JAALAS · 2024Article
- Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability.Drug metabolism and disposition: the biological fate of chemicals · 2024Article
- Evaluation and comparison of pharmacokinetic profiles and safety of two extended-release buprenorphine formulations in common marmosets (Callithrix jacchus).Scientific reports · 2023Article
- Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023Article
- EPD1504: a novel μ-opioid receptor partial agonist attenuates obsessive-compulsive disorder (OCD)-like behaviors.Frontiers in psychiatry · 2023Article
- Investigation of buprenorphine-related deaths using urinary metabolite concentrations.Drug testing and analysis · 2022Article
- A Novel Maintenance Therapeutic for Opioid Use Disorder.The Journal of pharmacology and experimental therapeutics · 2021Article
- High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Buprenorphine Evaluation in Plasma-Application to Pharmacokinetic Studies in Rabbits.Molecules (Basel, Switzerland) · 2021Article
- Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico.Pharmaceutics · 2020Article
- Quantifying enhanced risk from alcohol and other factors in polysubstance-related deaths.Forensic science international · 2020Article
- A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder.Journal of translational genetics and genomics · 2020Article
- Article
- Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.Journal of substance abuse treatment · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
aimsGender differences are known to occur in the pharmacokinetics of many drugs. Mechanisms may include differences in body composition, body weight, cardiac output, hormonal status, and use of different co-medications. Recently subtle gender-dependent differences in cytochrome P450 (CYP) 3A-dependent metabolism have been demonstrated. Buprenorphine N-dealkylation to norbuprenorphine is primarily performed by CYP3A. We therefore asked whether gender-dependent differences occur in the pharmacokinetics of buprenorphine.
methodsA retrospective examination was made of control (buprenorphine/naloxone-only) sessions from a number of drug interaction studies between buprenorphine and antiretroviral drugs. Twenty males and eleven females were identified who had a negative cocaine urine test prior to participation in the control session and were all on the same maintenance dose (16/4 mg) of sublingual buprenorphine/naloxone. Pharmacokinetic data from their control sessions (buprenorphine/naloxone only) were sorted by gender and compared using the two-sample t-test.
resultsFemales had significantly higher area under the plasma concentration curve (AUC) and maximum plasma concentrations for buprenorphine, norbuprenorphine and norbuprenorphine-3-glucuronide. AUCs relative to dose per body weight and surface area were significantly higher for only norbuprenorphine. AUCs relative to lean body mass were, however, not significantly different.
conclusionsGender-related differences exist in the pharmacokinetics of buprenorphine; differences in body composition appear to have a major impact; differences in CYPA-dependent metabolism may also contribute.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.